Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904186 | 0.91 | AURKA (0.43) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL14118837 | 0.91 | AURKA (0.42) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL14118759 | 0.91 | AKT1 (0.40) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL1905182 | 0.90 | AURKA (0.41) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL1906397 | 0.90 | AKT1 (0.39) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL14118884 | 0.87 | ALDH1A1 (0.41) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL14118738 | 0.84 | AKT1 (0.41) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL1904752 | 0.84 | AKT1 (0.41) | AKT1AKT2AURKACHEK1KIT | |
| SCHEMBL1906684 | 0.84 | AKT1 (0.41) | AKT1AKT2AURKACHEK1MAP2K1 | |
| SCHEMBL14118674 | 0.84 | AKT1 (0.42) | AKT1AKT2AURKACHEK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AURKA 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.